Archives of Orthopaedic and Trauma Surgery

, Volume 130, Issue 5, pp 583–589 | Cite as

Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty

Orthopaedic Surgery
First Online:
Received:

Abstract

Extended thromboprophylaxis is vital in patients undergoing total hip arthroplasty (THA) because of the prolonged risk of venous thromboembolism (VTE). Despite evidence that extended prophylaxis can reduce the incidence of symptomatic VTE in this high-risk patient population and the evidence-based guideline recommendations, a large proportion of patients still do not receive an adequate duration of thromboprophylaxis. This is partly due to the limitations of conventional anticoagulants, such as the subcutaneous route of administration or the requirement for routine coagulation monitoring and dose adjustment. New oral anticoagulants (such as the direct thrombin inhibitor dabigatran etexilate and the Factor Xa inhibitor rivaroxaban) could address the current unmet need. Phase III clinical studies in VTE prevention in patients undergoing THA and total knee arthroplasty (TKA) showed that dabigatran etexilate was non-inferior to the EU regimen of enoxaparin, but did not achieve non-inferiority to the US regimen of enoxaparin. In contrast, rivaroxaban demonstrated superiority to both enoxaparin regimens for the prevention of VTE after THA and TKA, without a significant increase in major bleeding rates. Their convenient, once-daily, fixed dosing, with no need for routine coagulation monitoring, could facilitate adherence to evidence-based guideline recommendations of extended thromboprophylaxis after THA.

Keywords

Total hip arthroplasty Venous thromboembolism Thromboprophylaxis Rivaroxaban Dabigatran etexilate 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The author would like to acknowledge Yong-Ling Liu of Chameleon Communications International, who provided editorial services with funding from Bayer Schering Pharma AG.

References

  1. 1.
    Kurtz S, Ong K, Lau E, Mowat F, Halpern M (2007) Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 89:780–785CrossRefPubMedGoogle Scholar
  2. 2.
    Seagroatt V, Tan HS, Goldacre M, Bulstrode C, Nugent I, Gill L (1991) Elective total hip replacement: incidence, emergency readmission rate, and postoperative mortality. BMJ 303:1431–1435CrossRefPubMedGoogle Scholar
  3. 3.
    Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edn. Chest 133:381S–453SGoogle Scholar
  4. 4.
    Lieberman JR, Hsu WK (2005) Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am 87:2097–2112CrossRefPubMedGoogle Scholar
  5. 5.
    Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ (2005) Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 93:76–79PubMedGoogle Scholar
  6. 6.
    Heit JA, Cohen AT, Anderson FA, on behalf of the VTE Impact Assessment Group (2005) Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood 106:910 (abstract)Google Scholar
  7. 7.
    Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M, VTE Impact Assessment Group in Europe (VITAE) (2007) Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 98:756–764Google Scholar
  8. 8.
    Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG (2004) Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:338S–400SCrossRefPubMedGoogle Scholar
  9. 9.
    Eikelboom JW, Quinlan DJ, Douketis JD (2001) Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358:9–15CrossRefPubMedGoogle Scholar
  10. 10.
    Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31–39CrossRefPubMedGoogle Scholar
  11. 11.
    Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA Jr (2008) Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 24:87–97PubMedGoogle Scholar
  12. 12.
    Warwick D, Friedman RJ, Agnelli G, Gil-Garay E, Johnson K, Fitzgerald G, Turibio FM (2007) Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 89:799–807CrossRefPubMedGoogle Scholar
  13. 13.
    Rahme E, Dasgupta K, Burman M, Yin H, Bernatsky S, Berry G, Nedjar H, Kahn SR (2008) Postdischarge thromboprophylaxis and mortality risk after hip-or knee-replacement surgery. CMAJ 178:1545–1554PubMedGoogle Scholar
  14. 14.
    Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA Jr (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371:387–394CrossRefPubMedGoogle Scholar
  15. 15.
    Dahl OE (2000) Continuing out-of-hospital prophylaxis following major orthopaedic surgery: what now? Haemostasis 30:101–105PubMedGoogle Scholar
  16. 16.
    Warwick D, Dahl OE, Fisher WD (2008) Orthopaedic thromboprophylaxis: limitations of current guidelines. J Bone Joint Surg Br 90:127–132CrossRefPubMedGoogle Scholar
  17. 17.
    Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J (1998) Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 158:2001–2003CrossRefPubMedGoogle Scholar
  18. 18.
    Skedgel C, Goeree R, Pleasance S, Thompson K, O’Brien B, Anderson D (2007) The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty. J Bone Joint Surg Am 89:819–828CrossRefPubMedGoogle Scholar
  19. 19.
    Bergqvist D, Jonsson B (1999) Cost-effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis following total hip replacement. Value Health 2:288–294CrossRefPubMedGoogle Scholar
  20. 20.
    Choay J, Lormeau JC, Petitou M, Sinay P, Fareed J (1981) Structural studies on a biologically active hexasaccharide obtained from heparin. Ann N Y Acad Sci 370:644–649CrossRefPubMedGoogle Scholar
  21. 21.
    Bauer KA, Eriksson BI, Lassen MR, Turpie AG (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345:1305–1310CrossRefPubMedGoogle Scholar
  22. 22.
    Eriksson BI, Bauer KA, Lassen MR, Turpie AG (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345:1298–1304CrossRefPubMedGoogle Scholar
  23. 23.
    Lassen MR, Bauer KA, Eriksson BI, Turpie AG (2002) Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359:1715–1720CrossRefPubMedGoogle Scholar
  24. 24.
    Turpie AG, Bauer KA, Eriksson BI, Lassen MR (2002) Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359:1721–1726CrossRefPubMedGoogle Scholar
  25. 25.
    Turpie AG, Eriksson BI, Lassen MR, Bauer KA (2002) A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc 11:182–188PubMedGoogle Scholar
  26. 26.
    Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:204S–233SCrossRefPubMedGoogle Scholar
  27. 27.
    Mismetti P, Laporte S, Zufferey P, Epinat M, Decousus H, Cucherat M (2004) Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost 2:1058–1070CrossRefPubMedGoogle Scholar
  28. 28.
    Stangier J, Rathgen K, Stahle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:292–303CrossRefPubMedGoogle Scholar
  29. 29.
    Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949–956CrossRefPubMedGoogle Scholar
  30. 30.
    Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR, RE-MODEL Study Group (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5:2178–2185CrossRefPubMedGoogle Scholar
  31. 31.
    Ginsberg J, Davidson B, Comp P, Francis CW, Friedman R, Huo M, Liberman JR, Muntz J, Raskob GE, Clements ML, Hantel S, Schnee J, Caprini JA (2008) The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24:1–9PubMedGoogle Scholar
  32. 32.
    Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939—an oral, direct Factor Xa inhibitor. J Thromb Haemost 3:514–521CrossRefPubMedGoogle Scholar
  33. 33.
    Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78:412–421CrossRefPubMedGoogle Scholar
  34. 34.
    Kubitza D, Becka M, Roth A, Mueck W (2008) Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 24:2757–2765CrossRefPubMedGoogle Scholar
  35. 35.
    Xarelto® Summary of Product Characteristics (30-9-2008). Available at: http://www.xarelto.com/html/downloads/Xarelto_Summary_of_Product_Characteristics_30Sept2008.pdf. Accessed 18 May 2009
  36. 36.
    Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2006) No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin. J Clin Pharmacol. 46:11 (abstract)Google Scholar
  37. 37.
    Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2006) Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46:549–558CrossRefPubMedGoogle Scholar
  38. 38.
    Kubitza D, Becka M, Mueck W, Zuehlsdorf M (2006) Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct Factor Xa inhibitor—are not affected by aspirin. J Clin Pharmacol 46:981–990CrossRefPubMedGoogle Scholar
  39. 39.
    Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kalebo P, ODIXa-HIP Study Investigators (2006) A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59–7939), for thromboprophylaxis after total hip replacement. Circulation 114:2374–2381CrossRefPubMedGoogle Scholar
  40. 40.
    Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765–2775CrossRefPubMedGoogle Scholar
  41. 41.
    Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776–2786CrossRefPubMedGoogle Scholar
  42. 42.
    Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673–1680CrossRefPubMedGoogle Scholar
  43. 43.
    Lassen MR (2009) Is the preoperative administration of enoxaparin 40 mg necessary to optimally prevent the occurrence of venous thromboembolism after hip surgery? A subanalysis of two pooled randomized trials. J Thromb Haemost 7:889–891CrossRefPubMedGoogle Scholar
  44. 44.
    Rosencher N, Bonnet MP, Sessler DI (2007) Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies. Anaesthesia 62:1154–1160CrossRefPubMedGoogle Scholar
  45. 45.
    Pradaxa® (dabigatran etexilate); Summary of product characteristics (2008). Available at: http://www.pradaxa.com/Include/media/pdf/Pradaxa_SPC_EMEA.pdf. Accessed 18 May 2009
  46. 46.
    Maezawa K, Nozawa M, Aritomi K, Kubota M, Shitoto K, Kurosawa H (2008) Changes of D-dimer after total hip arthroplasty in patients with and without intraoperative heparin. Arch Orthop Trauma Surg 128:37–40CrossRefPubMedGoogle Scholar
  47. 47.
    Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P, BISTRO II Study Group (2005) A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 3:103–111CrossRefPubMedGoogle Scholar
  48. 48.
    Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kalebo P (2007) Dose-escalation study of rivaroxaban (BAY 59–7939)—an oral, direct Factor Xa inhibitor—for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 120:685–693CrossRefPubMedGoogle Scholar
  49. 49.
    Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kälebo P, ODIXa-HIP Study Investigators (2006) Oral, direct Factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4:121–128CrossRefPubMedGoogle Scholar
  50. 50.
    Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, Misselwitz F, Gent M (2005) BAY 59–7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 3:2479–2486CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Department of OrthopaedicsÅrhus University HospitalÅrhus CDenmark

Personalised recommendations